Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury
Recruiting now
Conditions studied: Acute Kidney Injury
In brief
To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).
Key facts
- Study ID
- NCT07197957
- Run by
- BayCare Health System
- People needed
- 100
- Starts
- 2025-03-11
- Expected to finish
- 2027-02-28
- Last updated by the study team
- 2025-09-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects ages 18 years and above
- Inpatients with CKD (Figure 1)
- Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media.
- Pre and post contrast available
- All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study.
You may not qualify if…
- Preexisting dialysis
- Patients under the age of 18 years
- Pregnancy
- Incarcerated individuals
- Patients with impaired cognition and unable to follow consent procedures
- Recent exposure to CM (within 2 days before/after procedure)
- Cardiac shock
- Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim
Where it is running
- Morton Plant Hospital — Clearwater, Florida, United States (enrolling)
- Morton Plant North Bay Hospital — New Port Richey, Florida, United States (enrolling)
- Mease Countryside Hospital — Safety Harbor, Florida, United States (enrolling)
- St. Anthony's Hospital — St. Petersburg, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.